The deadly macrophage activation syndrome (MAS) constitutes one of the few rheumatologic emergencies. MAS is part of a larger group of diseases referred to as hemophagocytic syndromes that are seen in infections, malignancies, or genetic immunodeficiencies. Because of the clinical similarity of these diseases, many clinicians are tempted to approach them all similarly, both in diagnostic criteria and treatment paradigms. New work in the field suggests that not all hemophagocytic syndromes are equal. We will review the latest literature from both human and murine models related to the diagnosis, etiology, and treatment of hemophagocytic syndromes including MAS.
INTRODUCTION
Macrophage activation syndrome (MAS) is a potentially life-threatening complication of a variety of inflammatory diseases. It is characterized by prolonged fever, peripheral cytopenias, splenomegaly, hepatitis, and often multiple organ dysfunction in the context of overwhelming inflammation. The term MAS is often reserved for this syndrome when it complicates rheumatic illnesses, particularly systemic juvenile idiopathic arthritis (sJIA), systemic lupus erythematosus (SLE), or Kawasaki disease. Other autoimmune/autoinflammatory diseases that have reported associations with MAS include ankylosing spondylitis, polyarteritis nodosa, dermatomyositis, and adult rheumatoid arthritis. It bears many clinical similarities to a disorder known as familial hemophagocytic lymphohistiocytosis (fHLH) that is caused by any of a number of genetic defects resulting in impaired cellular cytotoxicity. Reactive HLH is a term applied to this constellation of symptoms complicating infections (particularly with Epstein-Barr virus, EBV) or malignancy (particularly cutaneaous T-cell lymphomas), although some authors have extended the moniker MAS to these populations as well. The pathologic hallmark of all these diseases is the appearance of hemophagocytes (HPCs): activated macrophages that have engulfed other hematopoietic elements. HPCs can be found in the bone marrow, lymph nodes, spleen, or a variety of other organs. Being characterized by the presence of HPCs, MAS and HLH are grouped under the term hemophagocytic syndromes.
Grom and Mellins [1] provided an excellent overview of this topic in 2010, and we would direct the unacquainted reader to this and other reviews of the field. The current review will touch on recent advances in diagnosis and treatment, but will particularly focus on novel insights into the pathogenesis of hemophagocytic syndromes.
DIAGNOSIS
The diagnoses of hemophagocytic syndromes must be accompanied by a high level of clinical suspicion and occur in the context of an evaluation for a variety of cytokine storm syndromes. There is an increasing appreciation for the similarities between MAS, HLH, and severe infection/sepsis that includes the frequent identification of HPCs in septic patients [2, 3] . Recent work in animal models also supports a likely overlap between sepsis, severe allergic reaction, and MAS/HLH [4, 5] . This overlap makes it tempting to consider all of these syndromes as roughly equivalent. However, the diagnostic distinctions between these diseases, although currently lacking a complete mechanistic understanding, are of critical importance in selecting the appropriate therapeutic strategy.
When followed by specific genetic testing, the criteria proposed by the Histiocyte Society in 2004 remain the gold standard for identification of patients with fHLH [6] . These criteria contain an evaluation of a patient's natural killer (NK) cell cytotoxic function and level of soluble interleukin-2 receptor a (sIL2Ra/sCD25). Since Stepp et al. [7] first described perforin gene mutations associated with HLH in 1999, several other gene products critical for proper packaging, exocytosis, or function of cytotoxic granules have been described, including Munc13-4, Munc18-2, Syntaxin 11, Rab27a, and Lyst (reviewed in [8] ). This list will continue to grow as whole exome/genome sequencing becomes more widely utilized. The HLH-04 criteria are, however, suboptimal for general diagnosis of hemophagocytic syndromes. First, NK cytotoxic function and sIL2Ra testing are not rapidly or widely available. Second, many investigators have noted the absence of HPCs early in the course of disease, both in MAS and in fHLH [9, 10] . Third, these criteria do not perform well in distinguishing MAS from a flare of the primary disease in which it occurs (especially rheumatic diseases such as sJIA and SLE) or from sepsis.
The disease most associated with MAS is sJIA, and although features of MAS are seen in up to 50% of sJIA patients [9] , fulminant MAS occurs in roughly 10%. The difficulty in distinguishing MAS from an sJIA flare has led Ravelli et al. [11] to investigate diagnostic criteria for this purpose. Using retrospective chart reviews and surveying experts, they identified certain clinical features suggestive of MAS versus sJIA flare, such as CNS dysfunction, hepatitis, and disseminated intravascular coagulopathy (DIC). Laboratory features suggestive of MAS versus sJIA flare included dropping platelet or leukocyte count, low erythrocyte sedimentation rate, low fibrinogen, high ferritin, and presence of bone marrow hemophagocytes [12] . The criteria proposed by Ravelli et al. [11] are listed below. The diagnosis of MAS requires the presence of any two or more laboratory criteria or of any two or three or more clinical and/or laboratory criteria. A bone marrow aspirate for the demonstration of hemophagocytosis may be required only in doubtful cases.
(1) Laboratory criteria are (a) decreased platelet count ( 262 Â 10 9 /l), (b) elevated levels of aspartate aminotransferase (>59 U/l), (c) decreased white blood cell count ( 4.0 Â 10 9 /l), and (d) hypofibrinogenemia ( 2.5 g/l). It should be noted that these criteria are only to be used in distinguishing MAS from a flare of SJIA, and not as general diagnostic criteria. Although these criteria are useful for inclusion of MAS patients
KEY POINTS
Although they share a similar clinical phenotype, it is likely that the different hemophagocytic syndromes arise from different pathogenic mechanisms.
Treatment of the different hemophagocytic syndromes is likely to require individualization to the particular clinical scenario rather than a common protocol for all.
Because of the likely different in pathogenic mechanisms, it is important to separate the distinct hemophagocytic syndromes in research design.
for retrospective studies, their performance has not yet been tested prospectively.
Additionally, a few recent studies have highlighted other tests of potential diagnostic utility. In both MAS and HLH, very high ferritin levels have been used as markers of macrophage and dendritic cell activation. Recent data suggest that very high ferritin levels, and failure of the ferritin to fall dramatically with treatment, are poor prognostic signs across all HLH subtypes [13] . Neopterin, an acute phase reactant and byproduct of nitric oxide synthesis, is produced by activated macrophages and was evaluated in patients with suspected HLH (familial and reactive). Neopterin was found to be elevated in HLH patients versus a comparator population with juvenile dermatomyositis and correlated strongly with ferritin [14] . CD107a, also known as lysosomal-associated membrane protein 1 (LAMP1), is a membrane protein expressed on the surface of cytotoxic cells following degranulation. Patients with genetic defects in degranulation associated with fHLH were shown to have defective CD107a mobilization to the cell surface upon ex-vivo stimulation, making this a rapid functional assay defect in degranulation [15] .
PATHOGENESIS
Recent work has provided new details into the mechanisms that underlie disease in both primary HLH and in secondary forms of HLH/MAS.
Novel insights into cytotoxic defects
It is well established that defects in the production, transport, exocytosis, or function of CD8 T-cell or NK cell cytotoxic granules can lead to HLH. The variety of such defects includes the pore-forming protein perforin itself, but also proteins critical for sorting of lysosomal protein (AP3b1, as seen in Hermansky-Pudlak syndrome), lysosomal fission (lyst, as seen in Chediak-Higashi syndrome), tethering (Rab27a), lysosomal packaging and priming of membrane fusion (Munc13-4), and membrane fusion (Munc18-2 and Syntaxin 11). The diseases related to these defects and the murine models associated with each have been recently and thoroughly reviewed [8] . In each model, uncontrolled CD8 T-cell production of interferon g (IFNg) appears to be the primary driver of disease.
Adding to the paradigm that IFNg is a critical proinflammatory mediator is a recent study by Zoller et al. [16 && ] showing that IFNg alone delivered via osmotic pump is sufficient to cause hemophagocytosis and anemia. They further show that the anemia seen in various IFNg-mediated disease models is dependent on monocytes responding to IFNg, and that mice with monocytes that lack the ability to respond to IFNg are protected against both anemia and hemophagocytosis. They call this process the 'consumptive anemia of inflammation' and show evidence to suggest that hemophagocytosis is a macropinocytic process (as opposed to receptor-mediated) similar to phagocytosis of apoptotic cells. These data support IFNg as a critical cytokine for driving hemophagocytic diseases. This study also supports a pathogenic role for HPCs by correlating the absence of anemia and hemophagocytosis to monocytes incapable of responding to IFNg. This is in contrast to data suggesting HPCs may be bystander or regulatory cells based on expression of scavenger receptors or markers of alternative activation [4, 17] .
The same group also recently described a mechanism by which the combination of viral infection and cytotoxic dysfunction might result in HLH. Lykens et al. [18 & ] show that, rather than excessive viremia, enhanced antigen presentation is responsible for T-cell hyperactivation (in both CD8 and CD4 compartments) in perforin-deficient/ lymphocytic choriomeningitis (LCMV)-infected mice, and this activation does not correlate with viral load. Rather than seeing enlarged antigenpresenting cell (APC) populations, they observed an enhanced ability of APCs that matured in a perforin-deficient environment to activate T cells regardless of the T-cell perforin status. These data suggest that a major function of cellular cytotoxicity is the regulation of antigen presentation, and not merely the killing of infected cells. They also suggest that HLH is caused by problems with the regulation of inflammation, rather than a primary problem with excessive proinflammatory stimuli (like uncontrolled viremia). Further, these data support targeting APC populations as a viable strategy for the treatment of hemophagocytic syndromes, particularly in patients with a defect in cytotoxicity.
Novel pathogenic pathways in hemophagocytic lymphohistiocytosis/ macrophage activation syndrome
The current literature is beginning to clarify the extent to which MAS and HLH are overlapping diseases. Although inclusion in HLH studies generally follows the HLH-04 criteria [6] , determination of which patients have MAS is often made at the investigators' discretion and varies from study to study. Nonetheless, studies showing impaired NK cell function, perforin gene defects, or Munc13-4 gene defects in some patients with sJIA complicated by MAS support impaired cytotoxic function as an important causative factor in at least a subset of MAS patients [19] [20] [21] . Other data, however, suggest heterogeneity within MAS/reactive HLH depending on the underlying disease. Maruyama and Inokuma [22] evaluated selected cytokines in predominantly adult women with various rheumatic illnesses. They found that macrophage colony-stimulating factor (M-CSF) and interleukin-18 were elevated in all MAS patients, but SLE patients had more M-CSF, whereas adult-onset Still's disease patients had substantially more interleukin-18. Further supporting heterogeneity in MAS, Shimizu et al.
[23] measured selected cytokines in MAS associated with sJIA, Kawasaki disease, and EBV. They found interleukin-18 was highly elevated in the sJIA-MAS patients regardless of disease activity, neopterin elevations were restricted to EBV-HLH patients, and IL-6 elevations were most impressive in kawasaki disease-MAS. Although these data do little to clarify pathogenic mechanisms, they underscore the necessity of studying MAS in the context of its underlying disease.
In an attempt to examine human cells in an animal model, Sato et al.
[24] infected immunodeficient mice reconstituted with normal human stem cells with EBV. These mice developed HLH with cytopenias, hemophagocytosis, expansion of activated CD8 þ T cells, and elevated IFNg. In contrast to the previous study, cytokinemia and T-cell expansion in this model correlated with viral load, and most T cells were not EBV-specific, suggesting that the antigen-presenting ability of host APCs may not be the sole determinant of disease. This study did not examine cytotoxic defects directly, and thus it is unclear why genetically 'normal' human hematopoietic cells are prone to the development of HLH in this context, but may relate to the antigenpresenting ability of infected B cells.
Further illustrating the difficulty of extending conclusions from murine models to fHLH patients, Sumegi et al.
[25] performed peripheral blood mononuclear cell (PBMC) microarrays on patients thought to have fHLH in comparison with healthy controls. Curiously, IFNg and IFNg-inducible genes were not significantly upregulated. Various other proinflammatory genes were highly upregulated, including those encoding interleukin-1a, interleukin-b, interleukin-6, and interleukin-8, as well as anti-inflammatory genes such as those encoding the interleukin-1 receptor antagonist, interleukin-10, and SOCS3. Interestingly, they observed downregulation of a number of genes associated with NK and CD8 T-cell activation, Toll-like receptor (TLR) signaling and genes regulating apoptosis. The active downregulation of such genes in sick patients suggests these may be pathways important for disease initiation.
TLR signaling has recently emerged as a potentially important mechanism for disease causation in HLH and MAS. A recent study by Krebs et al. [26] showed that signaling through molecules critical for TLR function may be critical for development of HLH in mice with defective cytotoxicity. This group has previously shown that mice lacking functional Munc13-4 develop an HLH-like syndrome after exposure to LCMV [27] . The recent study demonstrates that mice defective in Munc13-4 that are also defective in MyD88 (a critical signaling protein downstream of most TLRs and the interleukin-1 receptor) are almost entirely protected from developing HLH after LCMV infection. Such mice are able to clear the virus but do not have the same signs of APC and T-cell activation as mice with only the cytotoxic defect.
Additionally, stimulation through TLR9 alone was recently shown to result in an MAS-like syndrome in wild-type mice, but with the absence of HPCs TREATMENT A number of case reports and small case series have recently emerged that suggest new treatment strategies for MAS and HLH. Unsurprisingly, many of these modalities focus on the context in which the hemophagocytic syndrome occurs to guide treatment.
The protocol set forth in HLH-04 remains the primary treatment for patients diagnosed with fHLH [6] . The risks of infection, severe side effects, treatment-related malignancies, and death related to this protocol are quite high [2, 32] , and much empirical work has been done in both fHLH and MAS patients to reduce or avoid these risks. In fHLH, allogeneic bone marrow transplant (BMT) remains the only potentially curative option, but reduced-intensity induction or use of specific T-cell depleting agents have shown promise [32, 33] . On the basis of the successes with the use of interleukin-1-blocking agents, primarily anakinra, in patients with sJIA, some investigators have reported success with higher doses in the treatment of MAS complicating sJIA as well as other rheumatic illnesses [34, 35] . Fewer reports exist of successes with inhibitors of tumor necrosis factor a in MAS [36] , concordant with animal models suggesting this cytokine is not a critical driver of HLH/MAS [26,28 && ,37]. The use of interleukin-6 antagonism has not yet been reported as a treatment for MAS, perhaps out of concern for worsening of leukopenia. Additionally, the use of rituximab, ostensibly to deplete infected B cells, has shown success in conjunction with immunosuppressive chemotherapy in EBV-HLH [38] .
CONCLUSION
We have presented several novel lines of evidence to suggest that, despite clinical similarities, it may be both incorrect and dangerous to consider the hemophagocytic syndromes as a single entity. Recent human and murine investigations into these diseases demonstrate that different fundamental insults (cytotoxicity defects versus heightened TLR activity) can give rise to the syndrome. Furthermore, heterogeneity is highlighted clinically by the different mixes of cytokines found in the serum depending on the underlying disease. Therefore, it is likely wise to continue considering fHLH, the various rheumatic-associated MAS syndromes, and reactive HLH as separate entities. Clinically, their different underlying pathoetiologies will require different treatment protocols. From a research perspective, considering what are likely different diseases as a single group may confound our ability to make important discoveries. In practice, this is evident from the fact that sJIA-MAS can be successfully treated with interleukin-1b blockade, EBV-HLH with rituximab, and yet fHLH requires allogeneic BMT, further illustrating the need to tailor therapy to the clinical scenario rather using the same strict protocol for all. A major goal of future research should be to more completely define the initiating and propagating mechanisms of disease in these various scenarios in order that we may identify at risk patients, and rationally select the therapies to treat them. This study uncovers a novel cell extrinsic role for perforin in the regulation of antigen presenting cells providing greater insight into the mechanisms underlying fHLH. Importantly, this work separates viral load from disease progression, indicating that more than just persistent viremia is required for the development of hemophagocytic syndrome. 28.
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